Leprosy: Treatment and management of complications

Maymone, Mayra B.C.; Venkatesh, Samantha; Laughter, Melissa R.; Abdat, Rana; Hugh, Jeremy; Dacso, Mara M.; Rao, P Narasimha; Stryjewska, Barbara M.; Dunnick, Cory A.; Dellavalle, Robert P.

doi:10.1016/j.jaad.2019.10.138

Cited by 89 publications

(101 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypoesthesia ulcers can also be found. 2,5 The manifestation of skin disorders in the form of hyperpigmented patches was found mostly in type BL, amounting to 3 people (20%). Erythematous nodules were also found mostly in type BL, amounting to 3 people (20%), as shown in Table 4.…”

Section: Resultsmentioning

confidence: 99%

Epidemiology of Leprosy in Childhood: A Retrospective Study

Rusmawardiana¹,

Argentina²,

Sari³

2021

bsm

View full text Add to dashboard Cite

A B S T R A C TBackground: Children are the group most susceptible to Mycobacterium lepraeinfection. The proportion of new leprosy cases in children is indicator of successfulleprosy elimination program from World Health Organization (WHO), so this studywould like to know the epidemiology of pediatric leprosy at Dermatology andVenereology Polyclinic, Dr. Mohammad Hoesin Palembang. Methods:Retrospective study of all new cases of leprosy in children (0-17 years) who cameto Dermatology and Venereology Polyclinic, Dr. Mohammad Hoesin Palembangfrom January 2017 to December 2020. Results: There were 10 pediatric patients(7.58%) from 132 new leprosy cases. Most cases (40%) were in the 15-17 agegroup. There are more male than female. Most types of leprosy are BL (60%)followed by TT (20%). Manifestations of hyperpigmented skin patches and nervousdisorders, grade 1 disability, and type 2 leprosy reactions are mostly found in typeBL leprosy. The duration of illness 6-12 months has a grade 1 disability (30%).The history of positive contact came from same household in 3 cases (30%) with7 people (70%) domiciled in Palembang. All cases received Multidrug Therapy(MDT) treatment according to WHO guidelines. Conclusion: Found 10 new casesof leprosy in children in Dermatology and Venereology Polyclinic Dr. Moh. HoesinPalembang for four years, especially in the 15-17 age group, with the most casesbeing type BL leprosy. Household contact still plays an important role in leprosytransmission.

show abstract

Section: Resultsmentioning

confidence: 99%

Epidemiology of Leprosy in Childhood: A Retrospective Study

Rusmawardiana¹,

Argentina²,

Sari³

2021

bsm

View full text Add to dashboard Cite

show abstract

“…Antibiotics cure the bulk of cases of leprosy and the prescription of antibiotics with suitable dosage and period of administration depends upon the variety of the disease [51][52][53][54][55]. Mainly three drugs such as clofazimine (compound 1), rifampicin (compound 2), and dapsone (compound 3) are generally prescribed to treat leprosy infections [56][57][58].…”

Section: Treatment Available For Leprosymentioning

confidence: 99%

“…Recently, the WHO has proposed that single-dose treatment of patients with only 1 skin lesion with rifampicin, minocycline (Minocin), or ofloxacin (Floxin) is successful. Studies on other antibiotics are continuing [54,[59][60][61]. Several medical practitioners have used steroid treatments to cut back discomfort and acute leprosy inflammation; however, clinical trials have found no clear long-term effects on nerve damage.…”

Section: Review Articlementioning

confidence: 99%

A Review on Agents for the Treatment of Leprosy Infection

Ahmed

Anuradha

Wadhwa

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Leprosy is an ancient disease which is caused due to bacterial infection while curable but endures to be a substantial health problem in numerous parts across the world. It is an extremely contagious disease that is caused by any of 3 strains of bacteria such as Mycobacterium tuberculosis; Nontuberculous Mycobacterium; and Mycobacterium leprae. In several regions of Brazil, leprosy is a health issue which is still an endemic. Mainly skin, peripheral nerves, eyes, and mucosa of the upper respiratory tract are affected due to this chronic infection. As per the data shared by WHO across 159 countries globally, there were around 208,619 new leprosy cases reported. The global prevalence of leprosy is overcome with the aid of multidrug therapy which remains to be the chiefly targeted for treatment. The multidrug therapy gets attention as they show tremendous potential in fighting this disease. This review briefs about the different drugs and strategies which are used in treatment and superintendence of leprosy.

show abstract

“…Los fármacos de elección para el tratamiento de la enfermedad de Hansen son dapsona, clofazimina y rifampicina (14,15,2). Minociclina, claritromicina y ofloxacina se utilizan como alternativas para pacientes con intolerancia a alguno de los fármacos de elección (15,2). El régimen de tratamiento se debe escoger de forma individualizada, ya que va a depender del tipo de lepra y tasas de resistencia bacteriana (14).…”

Section: Tratamientounclassified

“…El régimen de tratamiento se debe escoger de forma individualizada, ya que va a depender del tipo de lepra y tasas de resistencia bacteriana (14). Previamente se utilizaba monoterapia, pero debido a la disminución en la efectividad del tratamiento se realizó el cambio hacia una terapia con múltiples fármacos (15). El esquema actual previene el desarrollo de resistencia y rápidamente disminuye la infectividad de los pacientes (16).…”

Section: Tratamientounclassified

El gran imitador: revisión bibliográfica de la lepra

Morúa

Lamuño

et al. 2021

View full text Add to dashboard Cite

show abstract

Leprosy: Treatment and management of complications

Cited by 89 publications

References 66 publications

Epidemiology of Leprosy in Childhood: A Retrospective Study

Epidemiology of Leprosy in Childhood: A Retrospective Study

A Review on Agents for the Treatment of Leprosy Infection

El gran imitador: revisión bibliográfica de la lepra

Contact Info

Product

Resources

About